News

  • Working from home? Check out new genetics data for Alzheimer’s disease research!

    The NIA is excited to announce the release of the latest genomics data set from the Alzheimer’s Disease Sequencing Project (ADSP). The NIA Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) is a vital tool as we seek to better understand genes that increase risk for — or protection from — AD/ADRD. Researchers can now access […]

  • NIAGADS DSS Releases 20K Whole Exomes

    NIAGADS is pleased to announce the release of 19,922 whole exomes called on GRCh38 through the Data Sharing Service (DSS). Nine different studies contributed to the release, including 10,088 ADSP Discovery Case Control WES samples, 3,144 ADGC African American WES samples, 75 Brkanac Families WES samples, 346 Corticobasal degeneration WES…

  • Event Recap: The Alzheimer’s Disease Genetics Consortium (ADGC) 10-Year Symposium

    Last month, on November 12 and 13, the Alzheimer’s Disease Genetics Consortium (ADGC) 10-Year Symposium took place at the Inn at Penn in Philadelphia, PA. The event was sponsored by the Perelman School of Medicine and the Department of Pathology and Laboratory Medicine, and it was organized by ADGC, Penn Neurodegeneration Genomics Center (PNGC) and […]

  • The Founders of PNGC

    The Penn Neurodegeneration Genomics Center was founded three years ago by Dr. Gerard Schellenberg and Dr. Li-San Wang. Together they have contributed over 40 years of their lives to Alzheimer’s research. How did you get started in Alzheimer’s research? Dr. Schellenberg: Dr. Schellenberg was offered a grant in 1982 for Alzheimer’s research. At the time, […]

  • PNGC at AAIC – 2019 Recap

    PNGC members had a great experience at the Alzheimer’s Association International Conference (AAIC) this year. AAIC took place in Los Angeles from July 12-17. We presented four posters during the conference and the National Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS) exhibited for the first time. In addition, Dr. Adam Naj […]

  • Additional ADSP Data Released

    We are pleased to announce a new data release on the NIAGADS Data Sharing Service (DSS). The NIAGADS DSS currently hosts ADSP Discovery+ Extension whole genome data from 854 subjects in 159 families and an additional 1433 cases and 1654 controls as well as 809 whole genomes from ADNI-WGS-1. Additional data…

  • Collaboration with ADNI

    In a collaboration with LONI, GCAD has recalled the 809 ADNI-WGS-1 whole genomes using the VCPA 1.0 pipeline and is releasing this data along with the 3985 ADSP whole genomes. Principal Investigators requesting this data must an approved application with ADSP through the DSS as well as ADNI. More information about this…

  • First Dataset Released

    The NIAGADS DSS currently hosts ADSP Discovery+ Extension whole genome data from 854 subjects in 159 families and an additional 1433 cases and 1654 controls as well as 809 whole genomes from ADNI-WGS-1. The first release includes the GATK called CRAMs and gVCFs generated by Genome Center for Alzheimer’s Disease…

  • NIAGADS DSS is now live!

    NIAGADS is pleased to announce that its Data Sharing Service is now live. The NIAGADS DSS hosts genomic data from the Alzheimer’s Disease Sequencing Project (ADSP) and other NIA funded AD genomic studies with approved users in the research community at large. The DSS hosts sequencing data mapped to GRCh38,…

  • Penn Medicine Press Release Highlights New Data Sharing Service

    Recently, Penn Medicine News wrote a press release describing the new NIAGADS Data Sharing Service (DSS), which will distribute genomic data to qualified investigators.  Initially, whole-genome sequence data will be available for 5,000 subjects, with more data to be released within a year. “Genetic findings for Alzheimer’s disease are critical for identifying targets for therapeutic […]

  • The State of Alzheimer’s Disease Genetics Research: A Discussion with Dr. Gerard Schellenberg

    • Human genetics helps us understand the biology of Alzheimer’s and identify drug targets.
    • Improvements in technology such as sequencing and gene therapy are promising.
    • Large sample sizes and rich phenotypes are critical to finding new AD genes.
    • Data visualization and outreach will encourage closer collaboration among the research community.